References
- Hodi FS, O'Day SJ, McDermott DF, . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
- Robert C, Thomas L, Bondarenko I, . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–26.
- Hanaizi Z, van Zwieten-Boot B, Calvo G. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012;48:237–42.
- Graziani G, Tentori L, Navarra P. Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res Epub 2011 Sep 10.
- Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab mediated diarrhea/colitis: Prevention of intestinal perforation and/or colectomy. J Clin Oncol 2008;26:9063.
- van den Eertwegh AJM, Bloemena E, Hoentjen F, van Bodegraven AA. Behandeling van auto-immuunreacties ten gevolge van een immuuntherapie met een antistof tegen CTLA-4 (ipilimumab) bij patiënten met een gemetastaseerd melanoom. Ned Tijdschr Oncol 2010;7:258–63.
- Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? Am J Clin Oncol Epub 2011 Feb 17.
- Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, . Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–9.
- Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, . Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23: 6043–53.
- Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, . Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009;27:9034.